Nemolizumab for Lichen Planopilaris

Overseen By Peter Friedman, MD PhD

Age: 18+

Sex: Any

Trial Phase: Phase 4

Sponsor: The Skin Center Dermatology Group

Must not be taking: JAK inhibitors, Biologics, DMARDs, Corticosteroids

Disqualifiers: Other alopecia, Systemic disease, Pregnancy, others

No Placebo Group All trial participants will receive the active study treatment (no placebo)

Prior Safety Data This treatment has passed at least one previous human trial

Compensation: Varies

Number of Visits: 3

Duration: 12 weeks

10 Participants Needed

What You Need to Know Before You Apply

What is the purpose of this trial?

Lichen planopilaris (LPP) is a primary lymphocytic cicatricial alopecia characterized by progressive, permanent hair loss and scalp symptoms such as pruritus and burning. Current treatments-including topical and intralesional corticosteroids, hydroxychloroquine, and immunosuppressants-are often inadequate, with limited evidence for efficacy and frequent treatment switching or discontinuation due to side effects or lack of response.1,2 Recent systematic reviews and meta-analyses highlight the need for new, targeted therapies. 3,4 Nemolizumab, an IL-31 receptor antagonist, FDA-approved for prurigo nodularis and atopic dermatitis, has demonstrated efficacy in pruritic and fibrosing dermatoses, making it a rational candidate for LPP.

Are You a Good Fit for This Trial?

This trial is for adults over 18 with Lichen Planopilaris, experiencing scalp itching. Participants must be willing to follow study procedures and agree to optional scalp biopsies. They should have a clinical diagnosis of LPP and an itchiness score of at least 4 out of 10.

Inclusion Criteria

I am willing and able to follow the study rules and sign the consent form.

I have itchy scalp.

I am 18 years old or older.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive nemolizumab injections every 4 weeks, with weight-based dosing

12 weeks

3 visits (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

• Nemolizumab

Trial Overview

The trial is testing Nemolizumab, an FDA-approved drug for skin conditions involving itchiness and inflammation. It's designed as a new treatment option for Lichen Planopilaris, which causes hair loss and scalp discomfort.

How Is the Trial Designed?

Group I: Patients receive nemolizumab injections every 4 weeks, weight based dosing Experimental Treatment 1 Intervention

Who Is Running the Clinical Trial?

The Skin Center Dermatology Group

Lead Sponsor

Trials

5

Recruited

170+